Tumorigenic and Metastatic Activity of Human Thyroid Cancer Stem Cells

Thyroid carcinoma is the most common endocrine malignancy and the first cause of death among endocrine cancers. We show that the tumorigenic capacity in thyroid cancer is confined in a small subpopulation of stem-like cells with high aldehyde dehydrogenase (ALDH(high)) activity and unlimited replica...

Full description

Saved in:
Bibliographic Details
Published inCancer research (Chicago, Ill.) Vol. 70; no. 21; pp. 8874 - 8885
Main Authors TODARO, Matilde, IOVINO, Flora, STASSI, Giorgio, ETERNO, Vincenzo, CAMMARERI, Patrizia, GAMBARA, Guido, ESPINA, Virginia, GULOTTA, Gaspare, DIELI, Francesco, GIORDANO, Silvia, DE MARIA, Ruggero
Format Journal Article
LanguageEnglish
Published Philadelphia, PA American Association for Cancer Research 01.11.2010
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Thyroid carcinoma is the most common endocrine malignancy and the first cause of death among endocrine cancers. We show that the tumorigenic capacity in thyroid cancer is confined in a small subpopulation of stem-like cells with high aldehyde dehydrogenase (ALDH(high)) activity and unlimited replication potential. ALDH(high) cells can be expanded indefinitely in vitro as tumor spheres, which retain the tumorigenic potential upon delivery in immunocompromised mice. Orthotopic injection of minute numbers of thyroid cancer stem cells recapitulates the behavior of the parental tumor, including the aggressive metastatic features of undifferentiated thyroid carcinomas, which are sustained by constitutive activation of cMet and Akt in thyroid cancer stem cells. The identification of tumorigenic and metastagenic thyroid cancer cells may provide unprecedented preclinical tools for development and preclinical validation of novel targeted therapies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0008-5472
1538-7445
DOI:10.1158/0008-5472.can-10-1994